Experimental pharmacology of auromomycin in L1210 tumor cells in vitro and in vivo

T. S A Samy, P. J. Siegel, W. E. Hopper, A. Krishan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The antibiotic protein auromomycin (AUR) is composed of a chromophore and an apoprotein. The in vitro cytotoxic activity of AUR is associated with the chromophore, whereas the apoprotein is not cytotoxic. Exposure to AUR blocks cell cycle traverse in G2-M phase. Both AUR and the chromophore exhibit antitumor activity against murine L1210 leukemia, both in vitro and in vivo. Similarly, neocarzinostatin and its chromophore also show antitumor activity against L1210 tumor cells in vitro and in vivo. AUR and neocarzinostatin apoproteins have no antitumor activity. The pharmacokinetics of 125I-labeled AUR in L1210 tumor-bearing mice shows a triexponential drug decay and initial rapid clearance of drug from the blood. The distribution of AUR-associated radioactivity into various tissues is rapid, and at the end of 24 hr, there is little drug accumulation in the tissues. During the first hr, greater than 50% of the administered drug is eliminated in the urine. As the chromophores alone possess antitumor activity, the effect of these antitumor proteins in cancer chemotherapy might be significantly increased by the administration of protein preparations containing biologically active and stable chromophores.

Original languageEnglish
Pages (from-to)3202-3207
Number of pages6
JournalCancer Research
Volume44
Issue number8
StatePublished - Jan 1 1984
Externally publishedYes

Fingerprint

Pharmacology
Apoproteins
Neoplasms
Pharmaceutical Preparations
Zinostatin
Leukemia L1210
Proteins
G2 Phase
auromomycin
In Vitro Techniques
Cell Division
Radioactivity
Cell Cycle
Pharmacokinetics
Urine
Anti-Bacterial Agents
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Samy, T. S. A., Siegel, P. J., Hopper, W. E., & Krishan, A. (1984). Experimental pharmacology of auromomycin in L1210 tumor cells in vitro and in vivo. Cancer Research, 44(8), 3202-3207.

Experimental pharmacology of auromomycin in L1210 tumor cells in vitro and in vivo. / Samy, T. S A; Siegel, P. J.; Hopper, W. E.; Krishan, A.

In: Cancer Research, Vol. 44, No. 8, 01.01.1984, p. 3202-3207.

Research output: Contribution to journalArticle

Samy, TSA, Siegel, PJ, Hopper, WE & Krishan, A 1984, 'Experimental pharmacology of auromomycin in L1210 tumor cells in vitro and in vivo', Cancer Research, vol. 44, no. 8, pp. 3202-3207.
Samy TSA, Siegel PJ, Hopper WE, Krishan A. Experimental pharmacology of auromomycin in L1210 tumor cells in vitro and in vivo. Cancer Research. 1984 Jan 1;44(8):3202-3207.
Samy, T. S A ; Siegel, P. J. ; Hopper, W. E. ; Krishan, A. / Experimental pharmacology of auromomycin in L1210 tumor cells in vitro and in vivo. In: Cancer Research. 1984 ; Vol. 44, No. 8. pp. 3202-3207.
@article{56be8386264540b6a3477880a7756da5,
title = "Experimental pharmacology of auromomycin in L1210 tumor cells in vitro and in vivo",
abstract = "The antibiotic protein auromomycin (AUR) is composed of a chromophore and an apoprotein. The in vitro cytotoxic activity of AUR is associated with the chromophore, whereas the apoprotein is not cytotoxic. Exposure to AUR blocks cell cycle traverse in G2-M phase. Both AUR and the chromophore exhibit antitumor activity against murine L1210 leukemia, both in vitro and in vivo. Similarly, neocarzinostatin and its chromophore also show antitumor activity against L1210 tumor cells in vitro and in vivo. AUR and neocarzinostatin apoproteins have no antitumor activity. The pharmacokinetics of 125I-labeled AUR in L1210 tumor-bearing mice shows a triexponential drug decay and initial rapid clearance of drug from the blood. The distribution of AUR-associated radioactivity into various tissues is rapid, and at the end of 24 hr, there is little drug accumulation in the tissues. During the first hr, greater than 50{\%} of the administered drug is eliminated in the urine. As the chromophores alone possess antitumor activity, the effect of these antitumor proteins in cancer chemotherapy might be significantly increased by the administration of protein preparations containing biologically active and stable chromophores.",
author = "Samy, {T. S A} and Siegel, {P. J.} and Hopper, {W. E.} and A. Krishan",
year = "1984",
month = "1",
day = "1",
language = "English",
volume = "44",
pages = "3202--3207",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Experimental pharmacology of auromomycin in L1210 tumor cells in vitro and in vivo

AU - Samy, T. S A

AU - Siegel, P. J.

AU - Hopper, W. E.

AU - Krishan, A.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - The antibiotic protein auromomycin (AUR) is composed of a chromophore and an apoprotein. The in vitro cytotoxic activity of AUR is associated with the chromophore, whereas the apoprotein is not cytotoxic. Exposure to AUR blocks cell cycle traverse in G2-M phase. Both AUR and the chromophore exhibit antitumor activity against murine L1210 leukemia, both in vitro and in vivo. Similarly, neocarzinostatin and its chromophore also show antitumor activity against L1210 tumor cells in vitro and in vivo. AUR and neocarzinostatin apoproteins have no antitumor activity. The pharmacokinetics of 125I-labeled AUR in L1210 tumor-bearing mice shows a triexponential drug decay and initial rapid clearance of drug from the blood. The distribution of AUR-associated radioactivity into various tissues is rapid, and at the end of 24 hr, there is little drug accumulation in the tissues. During the first hr, greater than 50% of the administered drug is eliminated in the urine. As the chromophores alone possess antitumor activity, the effect of these antitumor proteins in cancer chemotherapy might be significantly increased by the administration of protein preparations containing biologically active and stable chromophores.

AB - The antibiotic protein auromomycin (AUR) is composed of a chromophore and an apoprotein. The in vitro cytotoxic activity of AUR is associated with the chromophore, whereas the apoprotein is not cytotoxic. Exposure to AUR blocks cell cycle traverse in G2-M phase. Both AUR and the chromophore exhibit antitumor activity against murine L1210 leukemia, both in vitro and in vivo. Similarly, neocarzinostatin and its chromophore also show antitumor activity against L1210 tumor cells in vitro and in vivo. AUR and neocarzinostatin apoproteins have no antitumor activity. The pharmacokinetics of 125I-labeled AUR in L1210 tumor-bearing mice shows a triexponential drug decay and initial rapid clearance of drug from the blood. The distribution of AUR-associated radioactivity into various tissues is rapid, and at the end of 24 hr, there is little drug accumulation in the tissues. During the first hr, greater than 50% of the administered drug is eliminated in the urine. As the chromophores alone possess antitumor activity, the effect of these antitumor proteins in cancer chemotherapy might be significantly increased by the administration of protein preparations containing biologically active and stable chromophores.

UR - http://www.scopus.com/inward/record.url?scp=0021183415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021183415&partnerID=8YFLogxK

M3 - Article

C2 - 6589039

AN - SCOPUS:0021183415

VL - 44

SP - 3202

EP - 3207

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 8

ER -